Concepedia

Author

Vladimir Moiseyenko

Institute of Oncology NN PetrovORCID

Also Known As

Nikita Volkov, V M Moiseyenko, V Moiseyenko, V. M. Moiseyenko, V. Moiseyenko, V.M. . Moiseyenko, V.M. Moiseenko, V.M. Moiseyenko, Vitaliy Egorenkov, Vladimir M Moiseyenko

229

Publications

13K

Citations

40

H-Index

61

Concepts

All Affiliations

Institute of Oncology NN PetrovCity Clinical Oncology CenterSaint Petersburg State Pediatric Medical UniversityYonsei UniversityAstraZeneca (United Kingdom)
VM

About

Vladimir Moiseyenko is an author at Institute of Oncology NN Petrov specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

25

39

4.1K

2

Health Sciences

6

6

645

3

Gastroenterology

6

6

2.3K

4

Cell Biology

2

2

42

5

Public Health

1

1

13

Vladimir Moiseyenko

×

79

Publications

12.6K

Citations

40

H-Index

YearCitations

Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

Eric Van Cutsem, Vladimir Moiseyenko, Sergei Tjulandin,

Journal of Clinical Oncology

2006

1.9K

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Eric Van Cutsem, Josep Tabernero, Radek Lakomý,

Journal of Clinical Oncology

2012

1.4K

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang,

The Lancet

2018

1.3K

Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results

Joyce O’Shaughnessy, David Miles, Svetislava J. Vukelja,

Journal of Clinical Oncology

2002

1.1K

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

Florian Lordick, Yoon‐Koo Kang, Hyun Cheol Chung,

The Lancet Oncology

2013

830

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth,

JAMA Oncology

2020

616

Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

Jaffer A. Ajani, W. Rodriguez, G. Bodoky,

Journal of Clinical Oncology

2010

564

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

Eric Van Cutsem, István Láng, G D’Haens,

Journal of Clinical Oncology

2008

373

Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

Joyce O’Shaughnessy, Joanne L. Blum, Vladimir Moiseyenko,

Annals of Oncology

2001

305

Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

Alexander Burges, Pauline Wimberger, Carolin Kümper,

Clinical Cancer Research

2007

253

Page 1